Resistant Starch Prebiotic Effects in Chronic Kidney Disease

Inclusion Criteria:

• Participant is willing and able to give informed consent for participation in thetrial.

• Participant has the ability to speak and read English.

• Male or Female, aged 18 years or above. Females of child-bearing potential mustagree to use a medically approved method of birth control for the duration of thestudy. All hormonal birth control must have been in use for a minimum of threemonths. Acceptable methods of birth control include: Hormonal contraceptivesincluding oral contraceptives, hormone birth control patch, vaginal contraceptivering, injectable contraceptives, or hormone implant, double-barrier method,intrauterine devices, non-heterosexual lifestyle or agrees to use contraception ifplanning on changing to heterosexual partner(s), vasectomy of partner at least 6months prior to screening.

• Estimated glomerular filtration rate (eGFR) <15 mL/min/1.73m^2 for the past 3 months

• In the Investigator's opinion, participant is able and willing to comply with alltrial requirements.

Exclusion Criteria:

• The participant is cognitively impaired and cannot give consent or participate inthe group program

• The participant has an existing relationship with the research team, such assupervisory relationship (student, employee) or familial relationship (child,spouse, etc)

• Participants who indicate that they cannot consume study treatments.

• Participants who indicates they are allergic to potatoes or corn

• Female participant who is pregnant, lactating or planning pregnancy during thecourse of the trial.

• History of renal transplant, ongoing dialysis, use of antibiotics (last 3-months),bowel diseases, cancer, surgically removed bowel, or any gastrointestinal surgery (e.g. intestinal resection, gastric bypass, colorectal surgery)

• Inability to consume treatment due to swallowing or GI issues and inability toobtain written informed consent.

• Participating in another interventional trial that could influence the interventionor outcome of this trial.

• Participants with uncontrolled diabetes with a hemoglobin A1C > 10%.

• Participants who consume probiotic supplements.

• Participants with abnormal constrictions of the gastrointestinal tract, diseases ofthe oesophagus and/or the superior opening of the stomach (cardia), potential orexisting intestinal blockage, paralysis of the intestine, megacolon, faecalimpaction, appendicitis, a sudden change in bowel habits that has persisted for morethan 2 weeks, undiagnosed rectal bleeding, or failure to defaecate following the useof another laxative prod.

• Participants with severe anemia (hemoglobin less than 70).

• Participants taking medications which inhibit peristaltic movement (e.g.opioids,loperamide).

• Participants taking other fiber supplements or able to maintain high fiber/adequatefiber intake through diet.